THERAPY DOSSIER · th-2d37a06586aa

calcium-phosphate matrix with or without TGF-beta3

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 10

3 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00984581 ↗Injury indicationPHASE1/PHASE2completed

Safety, Tolerability, Systemic Exposure and Anti-scarring Potential of Intradermal Juvista in Women Aged 18-45

Cicatrix · Wound Healing

Enrolment: 35 · Results not recorded

NCT00977951 ↗Injury indicationPHASE1/PHASE2completed

Genomic Changes Associated With Accelerated Healing and Reduced Scarring Using RN1001

Cicatrix · Wound Healing

Enrolment: 20 · Results not recorded

NCT00978302 ↗Injury indicationPHASE1completed

Repeated, Escalating Concentrations of Intradermal RN1001 in Healthy Male Subjects

Cicatrix · Wound Healing

Enrolment: 55 · Results not recorded

NCT00432211 ↗PHASE2unknown

Juvista (Avotermin, recombinant TGF-beta3) in Prevention or Improvement of Scar Appearance Following Scar Revision Surgery

Cicatrix

Enrolment: 60 · Results not recorded

NCT00629811 ↗PHASE2completed

Two Dosing Regimens of Avotermin (Juvista) for Scar Appearance at Approximated Wound Margins

Cicatrix

Enrolment: 78 · Results not recorded

NCT00432328 ↗PHASE2terminated

Juvista (Avotermin) for Scar Appearance in Patients Undergoing Bilateral Reduction Mammaplasty

Mammaplasty · Cicatrix

Enrolment: 39 · Results not recorded

NCT00627536 ↗PHASE2completed

Dose-Ranging Trial of Avotermin (Juvista) for Scar Appearance at Approximated Wound Margins

Cicatrix

Enrolment: 39 · Results not recorded

NCT00847795 ↗PHASE1/PHASE2completed

Accelerated Wound Healing and Antiscarring Potential of Intradermal RN1001 (Avotermin) in Subjects Aged 60+

Cicatrix

Enrolment: 42 · Results not recorded

NCT00836147 ↗PHASE1/PHASE2completed

Juvista 250 ng/100 uL/linear cm Following Excision of Ear Lobe Keloids

Keloid

Enrolment: 20 · Results not recorded

NCT07137130 ↗NAnot yet recruiting

Adipose-Derived MSC Secretome Products With Addition of TGF Beta 3 for Melasma Therapy

Melasma

Enrolment: 34 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21406666 ↗2011Reported benefit

Calcium-phosphate matrix with or without TGF-beta3 improves tendon-bone healing after rotator cuff repair.

RatWoundSprague-DawleyMalen = 96 rats (8 per group per timepoint)local injection at tendon-bone interfaceTGF-beta3 2.75 microgat acute repair

Model: supraspinatus tendon detachment and transosseous repair (rotator cuff)

Calcium-phosphate matrix plus TGF-beta3 increased repair strength and improved bone formation and collagen organisation at the tendon-bone interface.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…